Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Discover below the 4 awards winners from EuroCMR 2016:
"Myocardial Fibrosis is Prevalent in Obstructive Sleep Apnea and Associated with Hospitalization for Heart Failure or Death."
By Dr Yaron Fridman (Heart and Vascular Institute - University of Pittsburgh Medical Center - Pittsburgh, USA)
There is a high prevalence of myocardial fibrosis in patients with known or suspected heart disease and obstructive sleep apnea (OSA). ECV assessment improved stratification of cardiovascular risk in patients with OSA. Since myocardial fibrosis can mediate cardiovascular disease, it may be a promising cardiac magnetic resonance image-guided target.
"A Concealed Carcinoid Cardiac Metastasis Uncovered by Comprehensive CMR-based Tissue Characterization and Multimodality Imaging."
By Pier Giorgio Masci, MD, PhD (Centre for Cardiac MR - Cardiology Unit - Lausanne University Hospital - Lausanne, Switzerland)
"Late cardiotoxicity in low risk breast cancer survivors after contemporary anthracycline treatment: a 6 year 100 patient study"
By Dr Viviana Maestrini (Barts Heart Centre, University College London, UK - Department of Cardiovascular, Respiratory, Nephrological, Anesthesiological and Geriatric Sciences, Sapienza University of Rome, Rome, Italy"Sapienza", University of Rome, Italy - Institute of Sport Medicine and Science, Italian National Olympic Committee, Rome, Italy)
Background: Chemotherapy cures patients with cancer but anthracyclines (AC) are cardiotoxic. In clinical practice left ventricle ejection fraction (EF) changes are used to detect cardiotoxicity. However, routine surveillance should not be limited to assess EF alone due to EF limitation. Objectives: to explore the late cardiac effects of AC using advanced cardiac imaging and biomarkers in low-risk breast cancer survivors.
Methods: 132 women from a former study of AC (intermediate dose – mean dose 399±85.4 mg/m2) breast cancer therapy were traced. After exclusions (died, recurrent disease, pregnancy, did not wish to attend), 98 attended. These had been selectively recruited to have no cardiovascular risk factors and no previous radio/chemo-therapy. All subjects underwent baseline pre-chemotherapy cardiac magnetic resonance (CMR) imaging. Subjects were compared with an age-matched control group of healthy volunteers (HV, n=34) at follow-up. All underwent resting ECG, blood biomarkers, advanced echocardiography and CMR structure, function (with the original 2005 protocol) and T1 mapping (MOLLI) for ECV quantification.
Results: 98 women attended for follow up (age 55±8.5 years, mean 6 years post AC treatment), and no participants reported cardiac symptoms or fulfilled criteria for cardiotoxicity. Across the AC group, EF fell by -3.7±4.2% (range from -13 to +8%) over 6 years follow-up, although all measurements remained within the normal range. Patients with higher dose of AC (≥450mg/m2) had greater EF reduction compare to lower doses (4.6±3.7% versus 2.7±4.4%, p=0.030). There were no differences in standard CMR parameters between the AC and HV groups, except the LA was larger in the AC group. Native myocardial T1 was greater in AC (1052±30 vs 1037±31 msec, p=0.012). Mean ECV calculations were similar (0.28±0.029 vs 0.28±0.029, p=0.803), however, values were slightly higher when left (vs right) radiotherapy had been performed (0.29±0.030 vs 0.28±0.023, p=0.017). Echocardiography found lower systolic and diastolic myocardial velocities and global longitudinal strain parameters - but within the normal reference range - with greatest reductions in the AC group who had experienced an EF drop ≥5% by CMR.
Conclusion: Chemotherapy with AC causes a small non-clinical reduction in the cardiac function (however measured) with a dose-response relationship, as does left sided radiotherapy. These changes are however small and may be missed by EF measurements alone.
"The role of CMR in the acute phase of hospitalization: changing paradigms"
By Dr Estefania De Garate Iparraguirre (NIHR Bristol Cardiovascular Biomedical Research Unit, Bristol Heart Institute, University of Bristol, Bristol, UK)
© 2017 European Society of Cardiology. All rights reserved